EGPA at Diagnosis: A Comprehensive Single-Center Profile of Laboratory Findings and Clinical Evidence
International Journal of Molecular Sciences · 08.08.2026 · 27 (16) · 7116
DOI: 10.3390/ijms27167116 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.08.2026. Verfasst von Silvia Brunetto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, Allergy and Clinical Immunology Unit, "G. Martino" Hospital, University of Messina, 98124 Messina, …. Hauptthemen laut MEDLINE: Granulomatosis with Polyangiitis, Churg-Strauss Syndrome. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis. A key bio-logical hallmark is peripheral blood eosinophilia while antineutrophil cytoplasmic an-tibody (ANCA) positivity is not always present. Therefore, an early phase suspicion of EGPA leading to a correct diagnosis can be challenging. We performed an observa-tional cross-sectional study limited to baseline data on 38 patients between December 2019 and December 2025 at the Allergy and Clinical Immunology Unit, Messina, Italy. Data collection included eosinophil, neutrophil, and lymphocyte counts; ANCAs and antinuclear antibodies (ANAs); erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) determination; and the Birmingham vasculitis activity score (BVAS) questionnaire: Median eosinophil counts were 685 cells/µL, the neutro-phil-to-lymphocyte ratio (NLR) was 2.29, ESR median values were 24 mm/h, and CRPs were 1.99 mg/L. ANCAs were positive in five patients, and ANAs in 20. The trend in ANA+ patients was of lower median eosinophil counts and higher ESR and CRP me-dian values and median BVASs. General, nervous system, and ENT BVAS domains had higher scores.: Disease activity in EGPA at diagnosis can be difficult to recognize. We defined it as chameleon-like and could not be captured by specific immunological sig-natures. Therefore, an early diagnosis needs multidimensional assessment, integrating laboratory parameters with clinical scores. In our EGPA cohort, ANAs were detected in just over half the patients, suggesting that rather than acting as bystanders, these could help clinicians, together with eosinophil counts, NLRs, and BVASs, to suspect EGPA at an early stage for referral to specialized medical centers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Experimental Medicine, Allergy and Clinical Immunology Unit, "G. Martino" Hospital, University of Messina, 98124 Messina, Italy.
ORCID-Profile: Silvia Brunetto, Francesca Dimasi, Cristiano Maiolo, Emanuela Zumbo, Federica Buta, Luisa Ricciardi
Zitieren
APA
Brunetto, S., Dimasi, F., Maiolo, C., Zumbo, E., Buta, F., Gangemi, S., & Ricciardi, L. (2026). EGPA at Diagnosis: A Comprehensive Single-Center Profile of Laboratory Findings and Clinical Evidence. International Journal of Molecular Sciences, 27(16), 7116. https://doi.org/10.3390/ijms27167116
Vancouver
Brunetto S, Dimasi F, Maiolo C, Zumbo E, Buta F, Gangemi S, et al. EGPA at Diagnosis: A Comprehensive Single-Center Profile of Laboratory Findings and Clinical Evidence. International Journal of Molecular Sciences. 2026;27(16):7116. doi:10.3390/ijms27167116
BibTeX
@article{Brunetto2026,
author = {Brunetto, Silvia and Dimasi, Francesca and Maiolo, Cristiano and Zumbo, Emanuela and Buta, Federica and Gangemi, Sebastiano and Ricciardi, Luisa},
title = {EGPA at Diagnosis: A Comprehensive Single-Center Profile of Laboratory Findings and Clinical Evidence},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {16},
pages = {7116},
doi = {10.3390/ijms27167116}
}
EUVIMED